Heparin in acute ischemic stroke: The case for a new clinical trial

Cerebrovascular Diseases

Volumn 9, Issue SUPPL. 3, 1999, Pages 16-23

  Chamorro, A ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DANAPAROID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ANTICOAGULATION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL;

EID: 0032783567     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047550     Document Type: Conference Paper

References (46)

1. Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, Chan FL, Fong KY, Law CB, Wong AW, Woo J: Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-1593.
2. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349: 1569-1581.
3. Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators: Low-molecular-weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke. JAMA 1998; 279:1265-1272.
4. Hommel M, for the FISS bis Investigators Group: Fraxiparine in ischaemic Stroke Study (FISS bis). Cerebrovasc Dis 1988;8(suppl 4): 19.
5. Chamorro A: Anticoagulation and antiaggregation for acute cerebral ischemia; in Castillo J, Dávalos A, Toni D (eds): Management of Acute Ischemic Stroke. Barcelona, Springer, 1997, pp 97-108.
6. Frydman A: Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996;26(suppl):24-38.
7. Sherman DG, Dyken ML Jr, Gent M, Harrison MJG, Hart RG, Mohr JP: Antithrombotic therapy for cerebrovascular disorders. An update. Chest 1995;108(suppl):444-456.
8. Farced J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM: Are the available low-molecular-weight heparin preparations the same? Semin Thromb Hemost 1996;2(suppl 1):77-91.
9. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L: Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980;65:64-73.
10. Blajchman MA, Young E, Ofosu FA: Effects of unfractionated heparin, dermatan sulfate and low-molecular-weight heparin on vessel wall permeability in rabbits. Ann NY Acad Sci 1989;556:245-254.
11. Carter CJ, Kelton JG, Hirsh J, Cerksus AL, Santos AV, Gent M: The relationship between the hemorrhagic and antithrombotic properties of low-molecular-weight heparin in rabbits. Blood 1982;59:1239-1245.
12. Hirsh J, Levine MN: Low-molecular-weight heparin. Blood 1992;79:1-17.
13. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
14. Hull RD, Pineo GF: Therapeutic use of low-molecular-weight heparins. Haemostasis 1993; 23(suppl 1):2-9.
15. Kochanek PM, Hallenbeck JM: Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992;23:1367-1379.
16. Feuerstein GZ, Liu T, Barone FC: Cytokines, inflammation and brain injury: Role of tumor necrosis α. Cerebrovasc Brain Metab Rev 1994;6:341-360.
17. Pantoni L, Sarti C, Inzitari D: Cytokines and cell adhesion molecules in cerebral ischemia. Experimental bases and therapeutic perspectives. Arterioscler Thromb Vasc Biol 1998;18: 503-513.
18. Kishimoto TK, Rothlein R: Integrins, ICAMs and selectins: Role and regulation of adhesion molecules in neutrophil recruitment to inflammatory sites. Adv Pharmacol 1994;25:117-169.
19. Rothlein R: Overview of leukocyte adhesion. Neurology 1997;49(suppl 4):3-4.
20. Lasky LA: Selectins: Interpreters of cell specific carbohydrate information during inflammation. Science 1992;258:964-969.
21. Minami M, Kuraishi Y, Yabuuchi K, Yamazaki A, Satoh M: Induction of interleukin-1β mRNA in a rat brain after transient forebrain ischemia. J Neurochem 1991;59:390-392.
22. Liu T, Clark RK, McDonnell PC, et al: Tumor necrosis factor expression in ischemic neurons. Stroke 1994;25:1481-1488.
23. Arfors KE, Key K: Sulfated polysaccharides in inflammation. J Lab Clin Med 1993;121:201-202.
24. Bazzoni G, Nuñes AB, Mascellani G, et al: Effect of heparin, dermatan sulfate, and related oligoderivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med 1993;121: 268-275.
25. Clowes AW, Karnowsky MJ: Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977;265:625-626.
26. Diamond MS, Alon R, Parkos CA, et al: Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD18). J Cell Biol 1995;130:1473-1482.
27. Sy MS, Schneeberger E, McCluskey R, et al: Inhibition of delayed-type hypersensitivity by heparin depleted of anticoagulant activity. Cell Immunol 1983;82:23-32.
28. Dupas JL, Brazier F, Yzet T, Roussel B, Duchmann JC: Treatment of active Crohn's disease with heparin. Gastroentcrology 1997;11:A900.
29. Brazier F, Yzet T, Boruchowicz A, Colombel JF, Duchmann JC: Treatment of ulcerative colitis with heparin. Gastroenterology 1997;11: A872.
30. Dwarakanath AD, Yu LG, Brookes C, Pryce D, Rhodes JM: Sticky neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 1995;37:585-588.
31. Yanaka K, Spellman SR, McCarthy JB, Oegema TR, Low WC, Camarata PJ: Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. I. Protective mechanism. J Neurosurg 1996;85:1102-1107.
32. Tangelder GJ, Arfors KE: Inhibition of leukocyte rolling in venules by protamine and sulfated polysaccharides. Blood 1991;77:1565.
33. Ley K, Cerrito M, Arfors KE: Sulfated polysaccharides inhibit rolling in rabbit mesentery venules. Am J Physiol 1991;260:H1667.
34. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP: Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993;11:3253-3258.
35. Kitamura N, Yamaguchi M, Shimabukuro K, Miyasaka M, Nakano H, Kumada K: Heparin-like glycosaminoglycans inhibit leukocyte adhesion to endotoxin activated human vascular endothelial cells under nonstatic conditions. Eur Surg Res 1996;28:428-435.
36. Bonmann E, Júttler E, Krstel HE, Spranger M: Heparin inhibits induction of nitric oxide synthase by cytokines in rat microvascular endothelial cells. Neurosci Lett 1998;253:95-98.
37. Yanaka K, Spellman R, McCarthy JB, Low WC, Camarata PJ: Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. II. Dose-response effect and the therapeutic window. J Neurosurg 1996;85:1108-1112.
38. Chamorro A, Vila N, Saiz A, Alday M, Tolosa E: Early anticoagulation after cerebral embolic infarction: A safety study. Neurology 1995;45: 861-865.
39. Chamorro A, Vila N, Ascaso C, Elices E, Schonewille W, Blanc R: Blood pressure and functional recovery and acute ischemic stroke. Stroke 1998;29:1850-1853.
40. Chamorro A, Vila N, Ascaso C, Blanc R: Heparin in very early treatment of acute stroke with atrial fibrillation. The Lancet Stroke Conference, Montreal, Oct 1998.
41. Chamorro A, Vila N, Ascaso C, Blanc R: Heparin in acute stroke with atrial fibrillation. Clinical relevance of very early treatment. Arch Neurol 1999, in press.
42. Clark W, Hazel JS, Beamer N, Wynn M, Coull B: The initial acute phase response predicts long-term stroke recovery. Stroke 1996;27: 186.
43. Akopov SE, Simonian NA, Grigorian GS: Dynamics of polymorphonuclear leukocytes accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke 1996;27:1739-1743.
44. Vila N, Filella R, Deulofeu R, Ascaso C, Abellana R, Chamorro A: Cytokine-induced inflammation and long-term stroke functional outcome. J Neurol Sci 1999;162:185-188.
45. Chamorro A, Vila N, Ascaso C, Saiz A, Montalvo J, Alonso P, et al: Early prediction of stroke severity. The role of the erythocyte sedimentation rate. Stroke 1995;26:573-576.
46. Chamorro A, Vila N, Blanc R, Saiz A, Ascaso C, Deulofeu R: The prognostic value of the acute-phase response in stroke recurrence. Eur J Neurol 1997;4:491-497.